ValuentumAd

Official PayPal Seal

Best Idea Vertex Pharma Boosts Guidance (Again), Buying Back Stock While Awaiting Key Clinical Trials

publication date: Dec 1, 2021
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image Shown: Vertex Pharmaceuticals Inc is one of our favorite biotech ideas. Image Source: Vertex Pharmaceuticals Inc – Third Quarter of 2021 IR Earnings Presentation. 

Vertex Pharma has a robust drug pipeline, though all eyes are on its potential CTX001 treatment. Should the treatment receive the green light from key healthcare regulators, Vertex Pharma’s financial performance would benefit from a major growth catalyst. In the meantime, we think it is prudent for Vertex Pharma to continue leveraging its financial strength to repurchase sizable chunks of its stock. We like Vertex Pharma as an idea in the Best Ideas Newsletter portfolio.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.